| Venetoclax-based therapies for acute myeloid leukemia VA Guerra, C DiNardo, M Konopleva Best practice & research Clinical haematology 32 (2), 145-153, 2019 | 167 | 2019 |
| Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms AS Sperling, VA Guerra, JA Kennedy, Y Yan, JI Hsu, F Wang, AT Nguyen, ... Blood, The Journal of the American Society of Hematology 140 (16), 1753-1763, 2022 | 73 | 2022 |
| Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors AS Alotaibi, M Yilmaz, R Kanagal-Shamanna, S Loghavi, TM Kadia, ... Blood cancer discovery 2 (2), 125-134, 2021 | 55 | 2021 |
| A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome M Swaminathan, HM Kantarjian, M Levis, V Guerra, G Borthakur, ... Haematologica 106 (8), 2121, 2021 | 45 | 2021 |
| Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia VA Guerra, EJ Jabbour, F Ravandi, H Kantarjian, NJ Short Therapeutic Advances in Hematology 10, 2040620719849496, 2019 | 22 | 2019 |
| Activity of venetoclax-based therapy in chronic myelomonocytic leukemia G Montalban-Bravo, D Hammond, CD DiNardo, M Konopleva, ... Leukemia 35 (5), 1494-1499, 2021 | 18 | 2021 |
| Development of TP53 mutations over the course of therapy for acute myeloid leukemia Y Alwash, JD Khoury, M Tashakori, R Kanagal‐Shamanna, N Daver, ... American journal of hematology 96 (11), 1420-1428, 2021 | 15 | 2021 |
| Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia G Montalban-Bravo, R Kanagal-Shamanna, V Guerra, J Ramos-Perez, ... Am J Hematol 96 (2), E50-E53, 2021 | 11 | 2021 |
| Interim analysis of a phase ii study of the glutaminase inhibitor telaglenastat (Cb-839) in combination with azacitidine in advanced myelodysplastic syndrome (Mds) VA Guerra, JA Burger, GM Borthakur, E Jabbour, N Pemmaraju, TM Kadia, ... Blood 134, 567, 2019 | 11 | 2019 |
| Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic … V Guerra, CD Dinardo, M Konopleva, JA Burger, G Borthakur, E Jabbour, ... Journal of Clinical Oncology 37 (15_suppl), 7037-7037, 2019 | 7 | 2019 |
| Comprehensive analysis of genotype and prior exposures in therapy-related myeloid neoplasms (t-MNs) VA Guerra, Y Yuanqing, J Hsu, F Wang, M Alfayez, K Morita, X Song, ... Blood 134, 458, 2019 | 6 | 2019 |
| A phase I-II study of ruxolitinib (INCB18424) for patients with chronic myeloid leukemia with minimal residual disease while on therapy with imatinib VA Guerra, HM Kantarjian, GM Borthakur, S Verstovsek, A Pike, ... Blood 134, 5906, 2019 | 6 | 2019 |
| AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis K Saxena, M Konopleva, T Bhagat, VA Guerra, R Maduike, S Tiziani, ... Blood 136 (1), 31-32, 2020 | 4 | 2020 |
| Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure VA Guerra, J Ramos Perez, D Hammond, K Chien, R Kanagal-Shamanna, ... Blood 136 (1), 22-23, 2020 | 3 | 2020 |
| Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation D Hammond, C DiNardo, M Konopleva, G Borthakur, J Ramos Perez, ... Blood 136 (1), 36-37, 2020 | 3 | 2020 |
| Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia SH Cass, JWD Tobin, YD Seo, G Gener-Ricos, EZ Keung, EM Burton, ... Annals of Oncology 34 (9), 796-805, 2023 | 2 | 2023 |
| Outcomes of R-Mini-CHOP therapy for elderly patients with diffused large B cell lymphoma (DLBCL) and high-grade follicular lymphoma (FL) VA Guerra, M Ocampo, M Cusnir Blood 138, 4581, 2021 | 2 | 2021 |
| Sars-CoV2 antibody responses in patients with hematological malignancies following anti-CD20 therapy VA Guerra, M Ocampo, M Cusnir Blood 138, 3554, 2021 | 1 | 2021 |
| Acquired factor V inhibitor presenting as life threatening bleeding after initiation of apixaban. GMG Fortuna, V Guerra, G Chaaya Haemophilia 27 (5), 2021 | 1 | 2021 |
| Advances in Cholangiocarcinoma Treatment in the Personalized Medicine Era MC Kathrin Dvir, Gliceida M Galarza Fortuna, Nathaly Cortez, Veronica Guerra Open Journal of Hepatology 2 (2), 1-2, 2020 | 1* | 2020 |
